The end for AbbVie’s bestseller? US FDA approves Amgen’s Humira biosimilar
Amid ongoing patent litigation, the FDA has approved Amgen’s Amjevita: the first US biosimilar version of AbbVie’s top selling rheumatoid arthritis biologic Humira.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs